Peptides researched for cognitive decline
Peptides studied for neuroprotection, cognitive ageing and neurodegenerative-disease research.
Overview
Cognitive decline is one of the most clinically and personally consequential aspects of ageing. The pathophysiology is multifactorial: amyloid-β and tau accumulation in the most-discussed Alzheimer's pathology, but also vascular contribution, mitochondrial dysfunction in neurons, neuroinflammation, and chronic oxidative stress. Each of these axes has attracted peptide research.
This page surveys peptides with published cognitive end-point data — predominantly mitochondrially-derived peptides with neuroprotective effects, Khavinson short peptides with reported effects on hippocampal antioxidant gene expression, and the Russian-developed Semax class of regulatory peptides. It is a research-context overview, not a clinical protocol; no compound discussed here is licensed as an Alzheimer's-disease treatment by the MHRA.
Cognitive end-points are notoriously difficult to operationalise in peptide research. Animal models typically use spatial-memory tasks (Morris water maze, Barnes maze) and rely on inferential mechanistic chains; human work is sparse and predominantly open-label. The published evidence supports neuroprotective mechanisms but does not yet establish any peptide as a clinically useful cognitive intervention.
The biology being targeted
Neuronal ageing biology touches at least four addressable axes. The first is mitochondrial dysfunction in neurons, particularly hippocampal pyramidal cells and cortical neurons with high energetic demand. Reduced ATP synthesis, oxidised cardiolipin and impaired calcium-buffering contribute to neuronal vulnerability. Mitochondrially-derived peptides (Humanin, MOTS-c) and structural stabilisers (SS-31) touch this axis.
The second is direct anti-apoptotic signalling. Humanin's interaction with pro-apoptotic Bax, Bid and BimEL provides a mechanistic explanation for the original observation that Humanin protects cultured neurons from amyloid-β cytotoxicity. The 2001 Hashimoto et al. discovery paper established this mechanism, and subsequent work has extended it to ischaemic stroke and other neurodegeneration models.
The third is the antioxidant-defence axis. Pinealon and related Khavinson short peptides reportedly modulate hippocampal expression of SOD1, catalase and related antioxidant enzymes. The proposed mechanism is direct gene regulation via DNA-promoter-motif binding, a model that remains the most contested aspect of the Khavinson programme.
The fourth is BDNF and neurotrophin signalling, which is the target of the Semax peptide class developed in Russia from the 1990s. Semax is structurally derived from ACTH (4-10) and is reported to potently upregulate brain BDNF expression. We do not cover Semax in a dedicated peptide page on this site at this time; this protocol is the placeholder for that coverage.
Peptides researched in this protocol
The original neuroprotective mitochondrially-derived peptide. Discovered in surviving neurons from an Alzheimer's patient, protective against amyloid-β cytotoxicity at nanomolar concentrations. The 1,000-fold-more-potent S14G analogue (HNG) is the standard research compound. Plasma Humanin declines with age and is preserved in centenarian offspring (Yen et al. 2014, Aging Cell).
Khavinson tripeptide (EDR) positioned for neuroprotection. Reduces neuronal apoptosis in hypoxic and oxidative-stress models; modest improvements in spatial-memory performance in aged rodents in Russian-language literature. Independent replication limited.
Telomere-axis and pineal-axis peptide. Indirect relevance through restoration of circadian rhythm — sleep architecture is correlated with cognitive outcomes — and possibly through general gene-regulatory effects on aged neural tissue.
Stack combinations in the literature
Humanin (or HNG) + a mitochondrial-axis stabiliser (SS-31) is a mechanistically coherent combination targeting two distinct neuronal-ageing axes. No direct combination data is published.
Pinealon + Epitalon co-administration appears in the Khavinson-programme literature as a generalised pineal-neural-axis intervention. Direct cognitive-end-point combination trials are not published.
Russian-developed regulatory peptide protocols often combine Semax with the Khavinson short peptides; this combination is widely discussed in research-peptide literature but has not been independently replicated outside Russia.
Evidence summary
Strongest single piece of evidence: the original Humanin discovery paper (Hashimoto et al. 2001, PNAS) and the substantial body of in vitro and rodent work that followed. The neuroprotective mechanism is well-characterised in cell-culture and mouse models. The translational gap to human clinical efficacy in Alzheimer's disease remains substantial; no completed phase II or III trial of Humanin or any analogue has been registered for Alzheimer's.
Yen et al. 2014 (Aging Cell) — plasma Humanin levels decline approximately 30% between ages 30 and 70 and are preserved in centenarian offspring. This is the principal human-correlation dataset linking the peptide to longevity and, by extension, to neurocognitive ageing outcomes.
Pinealon evidence is largely confined to the Khavinson programme's in-house publications. Mechanistic case is plausible; independent replication and modern RCT data are absent.
Safety profile & UK regulatory framing
Across the three compounds covered, available preclinical safety data is favourable. Acute and sub-chronic toxicology has not produced organ-specific or mutagenic signals at doses dramatically exceeding the proposed pharmacological range.
The principal theoretical concern for broadly anti-apoptotic compounds like Humanin is the role of apoptosis in clearance of damaged or pre-malignant cells. Sustained inhibition of apoptotic pathways could in principle reduce this clearance, although no such signal has appeared in the available rodent literature.
Under UK law, none of the compounds is a licensed Alzheimer's-disease or cognitive-decline treatment. Standard UK pharmacological options for Alzheimer's are cholinesterase inhibitors and the NMDA antagonist memantine; none of these are peptides covered on this site.
Frequently asked questions
Is any peptide approved for Alzheimer's in the UK?
No. No peptide compound holds UK MHRA authorisation for Alzheimer's disease or any other cognitive-decline indication. Recently approved Alzheimer's therapeutics (lecanemab, donanemab) are monoclonal antibody biologics, not short research peptides.
Is Humanin clinically relevant or just a research curiosity?
Mechanistically it is significant — the first known mitochondrially-derived peptide, with well-characterised protection against amyloid-β cytotoxicity in cell culture and ischaemic neuronal injury in rodent models. Clinically, no completed phase II/III trial has been registered. The human evidence is correlative (plasma levels vs. longevity, vs. metabolic disease).
Does Pinealon improve memory?
In aged-rodent models, Pinealon administration produces modest improvements in spatial-memory task performance vs. age-matched vehicle controls (Kozina et al. 2014, Advances in Gerontology). Human cognitive-end-point data is limited to open-label Russian-language observational cohorts.
What about Cerebrolysin, Selank, Semax?
These are Russian-developed peptide therapeutics with reported neurocognitive effects. They fall outside the longevity-focused scope of this site but are well-documented in the Russian-language neurology literature. None holds UK MHRA authorisation.